Delayed Radioprotection by Thiols
硫醇的延迟辐射防护
基本信息
- 批准号:7059411
- 负责人:
- 金额:$ 29.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-07-01 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:antioxidantscatalasecell proliferationenzyme activityflow cytometrygene expressionglutathione peroxidasehydrogen peroxideimmunoprecipitationlaboratory mouseneoplasm /cancer radiation therapyneoplastic growthnuclear factor kappa betaperoxynitritesradiation dosageradiation sensitivityradioprotective agentssuperoxide dismutasethiolstissue /cell culturewestern blottings
项目摘要
DESCRIPTION (provided by applicant): The goal of this investigation is the characterization of the delayed radioprotective effect induced following exposure of cells to non-protein thiols (NPT). The underlying hypothesis is that NPT exposure of cells results in activation of the redox sensitive nuclear transcription factor kappaB (NFkappaB) and enhancement in manganese superoxide dismutase (MnSOD) gene expression followed by elevated intracellular levels of active MnSOD protein. MnSOD is an anti-oxidant protein that can confer protection against oxidative radical species induced by ionizing radiation. The ability of NPT to induce at a later time elevated MnSOD levels results in a delayed radioprotective effect that will have implications in radioprotection in general, and tumor protection in particular. This study focuses on four clinically approved NPT, amifostine, mesna, Nacetylcysteine (NAC), and captopril. These NPT are currently in clinical use, and the potential for their induction of a delayed radioprotective effect in tumors of patients undergoing cancer treatment is a here-tofore unrecognized problem. Four specific aims are proposed. Aim 1 seeks to test the hypothesis that NPT over a range of doses will enhance MnSOD gene expression, leading to elevated intracellular levels of active MnSOD protein accompanied by increased catalase and glutathione peroxidase (GPx) activities in cultured tumor and non-tumor cells. Aim 2 will test the hypothesis that elevated MnSOD activity will result in enhanced radioprotection, especially at 2 Gy. Aim 3 is focused on testing the hypothesis that either single or multiple exposures of animals to NPT will result in elevated MnSOD gene expression and protein activity in both normal and tumor tissues, the latter grown as pulmonary tumor nodules or solid tumors in the hind legs of animals. Aim 4 will test the hypothesis that elevated MnSOD activity will result in delayed radioprotection to selected normal and tumor tissues as determined by quantitative survival assays, i.e., spleen colony assay, intestinal microcolony assay, lung colony assay, and the TCD50 assay. Two alternative hypotheses will also be tested. One elevated MnSOD activity can result in anti-oxidant imbalance relating to catalase and GPx activities, resulting in hydrogen peroxide buildup and radiation sensitization. Two, elevation in MnSOD level without a concomitant increase in enzymatic activity can result from nitration of MnSOD by peroxynitrite (ONOO-).
描述(由申请人提供):本研究的目的是表征细胞暴露于非蛋白硫醇(NPT)后诱导的延迟辐射防护效应。潜在的假设是,细胞暴露于 NPT 会导致氧化还原敏感核转录因子 kappaB (NFkappaB) 的激活和锰超氧化物歧化酶 (MnSOD) 基因表达的增强,随后活性 MnSOD 蛋白的细胞内水平升高。 MnSOD 是一种抗氧化蛋白,可以针对电离辐射诱导的氧化自由基物种提供保护。 NPT 在稍后诱导 MnSOD 水平升高的能力导致延迟的辐射防护作用,这将对一般辐射防护,特别是肿瘤防护产生影响。本研究重点关注四种临床批准的 NPT:氨磷汀、美司钠、N乙酰半胱氨酸 (NAC) 和卡托普利。这些 NPT 目前正在临床使用,它们对接受癌症治疗的患者的肿瘤诱导延迟辐射防护作用的潜力是迄今为止尚未认识到的问题。提出了四个具体目标。目标 1 旨在检验以下假设:一定剂量的 NPT 将增强 MnSOD 基因表达,导致细胞内活性 MnSOD 蛋白水平升高,同时培养的肿瘤和非肿瘤细胞中过氧化氢酶和谷胱甘肽过氧化物酶 (GPx) 活性增加。目标 2 将检验以下假设:MnSOD 活性升高将导致辐射防护增强,尤其是在 2 Gy 下。目标 3 的重点是检验以下假设:动物单次或多次暴露于 NPT 会导致正常组织和肿瘤组织中 MnSOD 基因表达和蛋白质活性升高,后者在动物后腿中生长为肺肿瘤结节或实体瘤。目标 4 将检验以下假设:MnSOD 活性升高将导致对选定的正常组织和肿瘤组织的放射防护延迟,这是通过定量生存测定(即脾集落测定、肠微集落测定、肺集落测定和 TCD50 测定)确定的。还将测试两个替代假设。 MnSOD 活性升高会导致与过氧化氢酶和 GPx 活性相关的抗氧化失衡,从而导致过氧化氢积聚和辐射过敏。第二,过氧亚硝酸盐 (ONOO-) 硝化 MnSOD 可能导致 MnSOD 水平升高,但酶活性并未随之增加。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.
氨磷汀可在正常组织和可移植肿瘤中诱导抗氧化酶活性,从而影响放射反应。
- DOI:10.1016/j.ijrobp.2008.10.061
- 发表时间:2009-03-01
- 期刊:
- 影响因子:7
- 作者:Grdina, David J.;Murley, Jeffrey S.;Kataoka, Yasushi;Baker, Kenneth L.;Kunnavakkam, Rangesh;Coleman, Mitchell C.;Spitz, Douglas R.
- 通讯作者:Spitz, Douglas R.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID J. GRDINA其他文献
DAVID J. GRDINA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID J. GRDINA', 18)}}的其他基金
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
放射防护器和放射治疗联合化学预防
- 批准号:
8070528 - 财政年份:2009
- 资助金额:
$ 29.82万 - 项目类别:
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
放射防护器和放射治疗联合化学预防
- 批准号:
8245173 - 财政年份:2009
- 资助金额:
$ 29.82万 - 项目类别:
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
放射防护器和放射治疗联合化学预防
- 批准号:
8450913 - 财政年份:2009
- 资助金额:
$ 29.82万 - 项目类别:
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
放射防护器和放射治疗联合化学预防
- 批准号:
7728207 - 财政年份:2009
- 资助金额:
$ 29.82万 - 项目类别:
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
放射防护器和放射治疗联合化学预防
- 批准号:
7846235 - 财政年份:2009
- 资助金额:
$ 29.82万 - 项目类别:
相似国自然基金
木薯CC类谷氧还蛋白MeGRXC3修饰Catalase1蛋白调控过氧化氢酶活性的分子机制
- 批准号:32360458
- 批准年份:2023
- 资助金额:32.00 万元
- 项目类别:地区科学基金项目
Catalase调控滑膜巨噬细胞NLRP3炎症小体/Caspase-1/IL-1β轴修复骨关节炎软骨损伤的机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
转录因子(FOXO3a)对心肌细胞衰老调控的分子机理研究
- 批准号:30973151
- 批准年份:2009
- 资助金额:36.0 万元
- 项目类别:面上项目
视神经炎的多基因治疗研究
- 批准号:30471847
- 批准年份:2004
- 资助金额:21.0 万元
- 项目类别:面上项目
相似海外基金
Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After Radiation
针对线粒体氧化还原能力来克服放射后再生的癌症亚型
- 批准号:
10817512 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Racial disparities of open angle glaucoma: A study of mitochondria and oxidative stress in human trabecular meshwork
开角型青光眼的种族差异:人类小梁网线粒体和氧化应激的研究
- 批准号:
10735655 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Nitric oxide induced soluble guanylate cyclase dysfunction or activation: Implications as a disease indicator or in therapy
一氧化氮诱导可溶性鸟苷酸环化酶功能障碍或激活:作为疾病指标或治疗的意义
- 批准号:
10845936 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Subcellular-targeted CYP2E1 and alcohol in the brain
大脑中亚细胞靶向 CYP2E1 和酒精
- 批准号:
10496067 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Novel DNA cross-linking agents and combination strategies for tumor-specific activation
新型 DNA 交联剂和肿瘤特异性激活的组合策略
- 批准号:
10730787 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Pathophysiological Significance of Atrial Fibrillation Electrogram Patterns
心房颤动电图模式的病理生理学意义
- 批准号:
10634983 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Manganese dioxide as a nanozyme to mitigate oxidative stress in osteoarthritis
二氧化锰作为纳米酶可减轻骨关节炎的氧化应激
- 批准号:
10751638 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders
抗 HIV 和抗 COVID-19 药物和物质使用障碍的肝毒性机制
- 批准号:
10684434 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:
Commensal modulation of Peri-implant Microbiome Dysbiosis via Veillonella parvula
小韦荣球菌对种植体周围微生物群失调的共生调节
- 批准号:
10899342 - 财政年份:2023
- 资助金额:
$ 29.82万 - 项目类别:














{{item.name}}会员




